Literature DB >> 1738224

Effects of various enteral feeding products on postprandial blood glucose response in patients with type I diabetes.

A L Peters1, M B Davidson.   

Abstract

These studies were performed to evaluate the postprandial blood glucose responses to a variety of differently formulated enteral feeding products in patients with type I diabetes. Eleven subjects with type I diabetes were evaluated in three studies, all using a Biostator (artificial endocrine pancreas) that delivered a small, basal amount of insulin and measured blood glucose levels. Subjects consumed 20 mL of the assigned formula every 15 minutes for the 240 minutes of the study. Study 1 evaluated the response to each of five products: Glucerna, Enrich, Ensure HN, Pulmocare, and Compleat Modified. When the postprandial blood glucose response to Glucerna was greater than when its research formulation (EN-8715) had been tested in 1988, studies 2 and 3 were undertaken to assess why this discrepancy occurred. Study 2 compared stored EN-8715 to Glucerna and study 3 compared frozen and thawed vs nonfrozen EN-8715, because of a concern that the original product had been frozen during shipping. In study 1 the glucose response (assessed as area under the glucose curve) correlated with the grams of carbohydrate present in the enteral feeding formula (r = .58, p = .002). The presence or absence of fiber, in the form of soy polysaccharide, did not affect the glucose response. Glucerna produced a significantly lower blood glucose response than did Enrich, Ensure HN, or Compleat Modified, although this response was greater than the response to EN-8715 in 1988. However, in study 2 no differences were found between stored EN-8715 and Glucerna and in study 3, freezing and thawing was not found to significantly alter the glucose response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738224     DOI: 10.1177/014860719201600169

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  4 in total

1.  Open-label, randomized, multiple-center, parallel study comparing glycemic responses and safety profiles of Glucerna versus Fresubin in subjects of type 2 diabetes mellitus.

Authors:  Wei-Qing Wang; Yi-Fei Zhang; Da-Jin Zhou; Zhi-Min Liu; Xu Hong; Ming-Cai Qiu; Yong-Quan Shi; Pei-Jin Xia; Jin Lu; Mao-Jing Xu; Liang An; Wei Feng; Peng Zhang; J Schwamman; Guang Ning
Journal:  Endocrine       Date:  2008-04-10       Impact factor: 3.633

Review 2.  Inpatient enteral and parenteral [corrected] nutrition for patients with diabetes.

Authors:  Michael A Via; Jeffrey I Mechanick
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

3.  Effect of enteral nutritional products differing in carbohydrate and fat on indices of carbohydrate and lipid metabolism in patients with NIDDM.

Authors:  L J McCargar; S M Innis; E Bowron; J Leichter; K Dawson; E Toth; K Wall
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

Review 4.  Diabetes-Specific Nutrition Formulas in the Management of Patients with Diabetes and Cardiometabolic Risk.

Authors:  Jeffrey I Mechanick; Albert Marchetti; Refaat Hegazi; Osama Hamdy
Journal:  Nutrients       Date:  2020-11-25       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.